Skip to contentpdufa.bio

HWK-206 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

HWK-206 Phase is a Whitehawk Therapeutics, Inc. program in small-cell lung cancer and neuroendocrine tumors. Its next catalyst is a Readout in Q4 2027.

WHWK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Small-cell lung cancer and neuroendocrine tumors. Sponsor: Whitehawk Therapeutics, Inc. (WHWK). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027WHWK

Questions

When is HWK-206 Phase's next FDA decision or readout?

The next tracked catalyst for HWK-206 Phase is a Readout in Q4 2027.

What happened at HWK-206 Phase's most recent FDA decision?

No FDA decision for HWK-206 Phase is in our archive yet.

What is HWK-206 Phase used for?

In our records HWK-206 Phase is under review or in development for Small-cell lung cancer and neuroendocrine tumors.

Who makes HWK-206 Phase?

Whitehawk Therapeutics, Inc. (WHWK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.